a strong trendp = 0.02
Results showed a strong trend toward improved survival [hazard ratio (HR) 0.60, p = 0.02) in patients who received MVAC. 6 Because of the high incidence of adverse effects such as myelosuppression in patients taking MVAC, dose-dense MVAC (ddMVAC) was introduced which delivered the drug in two weekly cycles with growth factor support to abrogate this side effect. ddMVAC was well tolerated, with a ypT0 rate of 38% in one trial which included node-positive patients. 7 Numerous other trials were conducted in this space over the decades, some of which we have summarized below.